Catalent to Host Workshop to Discuss Accelerating Early Drug Development through Consultant Collaboration
SOMERSET, N.J. – December 17, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will host a workshop for drug development consultants titled, “How to Effectively Work with a Development Partner – From a Consultant Standpoint”, at its facility in San Diego, on Jan. 8, 2020.
The workshop will feature presentations from two experienced industry consultants: Alan F. Parr, Pharm.D., Ph.D., Managing Member, BioCeutics LLC whose discussion “Prepare Your Clients for Success: Tips and Strategies to Avoid Dangerous Pitfalls in Consulting”, will explain how a client’s primary goal and focus will impact the strategy used in the development of their asset; and Jim Spavins, Principal, Spavins Consulting LLC, who will present “Integrating the Business, Regulatory and Scientific Needs of a Client” and discuss how drug development relies on the integration of multi-disciplinary scientific, business and regulatory activities. He will explain how consultants should provide advice and services to support all three in order to successfully support a client’s program.
Also speaking at the event will be Lisa Caralli, Director of Science and Technology, Catalent, who will use case studies to show how consultants can help their clients get through early phase development faster, and avoid critical pitfalls in early drug development in her presentation, “Using the Developability Classification System and physiologically-based pharmacokinetic Modeling Tools to Select the Right Formulation Strategy when Transitioning Small Molecules from Discovery to the Clinic”.
Following the workshop, attendees will be given a tour of Catalent’s San Diego facility, which is one of three global centers of excellence in oral dose early-phase development focusing on preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules.
Dr. Parr is the former Director of Biopharmaceutics at GlaxoSmithKline, and has held various roles including formulation scientist and formulation manager. He has worked in the field of pharmaceutical sciences for 33 years, where his responsibilities ranged from development of formulations from early development through to scale up of commercial-scale batches.
Mr. Spavins has almost 40 years’ experience developing and bringing innovative new medicines to patients and is former senior vice president of Pfizer’s pharmaceutical sciences organization.
Ms. Caralli has over 27 years of industry experience, and in her role at Catalent, works with pharmaceutical companies to identify appropriate development pathways for early development drug candidates. She has previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals, and began her career at the Immune Response Corporation. Ms. Caralli holds a bachelor’s degree in biochemistry from the University of California at Davis, Davis, California.
To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR – richard@nepr.agency.
Notes for Editors
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com